| Berchman A Vaz, MD | |
|
535 N Wilmot Rd, #101, Tucson, AZ 85711-2600 | |
| (520) 874-7400 | |
| (520) 874-3425 |
| Full Name | Berchman A Vaz |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 36 Years |
| Location | 535 N Wilmot Rd, Tucson, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265468219 | NPI | - | NPPES |
| 777948 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 24870 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Catalina Pointe Arthritis And Rheumatology Specialists, Pc | 8628012564 | 10 |
News Archive
HHS' inspector general's office is launching an in-depth investigation into cases where Medicare hospice beneficiaries get inpatient care, following unusual billing patterns that surfaced during recent research on the $1.1 billion industry.
Emerging Healthcare Solutions, Inc. disclosed today that the Company has executed a Term Sheet with Stand-By Systems. The Term Sheet represents successful negotiations between the two companies just ahead of finalizing a Definitive Agreement. Stand-By Systems (SBS) owns the FDA approved SBS 1615 catalytic oxygen generator and associated systems. This cutting edge generator provides medical grade USP oxygen at the push of a button from self-contained inert dry compounds.
A study in the Feb. 1 issue of the journal SLEEP suggests that healthy older adults without sleep disorders can expect to have a reduced "sleep need" and to be less sleepy during the day than healthy young adults.
Cell Therapeutics, Inc. today announced that it has entered into a securities purchase agreement to sell, subject to certain closing conditions, up to $25.0 million of shares of its Series 8 Non-Convertible Preferred Stock, warrants to purchase up to 22,563,177 shares of common stock and an additional investment right to purchase up to $25.0 million of shares of its Series 9 Convertible Preferred Stock, in a registered offering to a single life sciences institutional investor.
Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.
› Verified 5 days ago
| Entity Name | Catalina Pointe Arthritis & Rheumatology Specialists, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659493120 PECOS PAC ID: 8628012564 Enrollment ID: O20050613000528 |
News Archive
HHS' inspector general's office is launching an in-depth investigation into cases where Medicare hospice beneficiaries get inpatient care, following unusual billing patterns that surfaced during recent research on the $1.1 billion industry.
Emerging Healthcare Solutions, Inc. disclosed today that the Company has executed a Term Sheet with Stand-By Systems. The Term Sheet represents successful negotiations between the two companies just ahead of finalizing a Definitive Agreement. Stand-By Systems (SBS) owns the FDA approved SBS 1615 catalytic oxygen generator and associated systems. This cutting edge generator provides medical grade USP oxygen at the push of a button from self-contained inert dry compounds.
A study in the Feb. 1 issue of the journal SLEEP suggests that healthy older adults without sleep disorders can expect to have a reduced "sleep need" and to be less sleepy during the day than healthy young adults.
Cell Therapeutics, Inc. today announced that it has entered into a securities purchase agreement to sell, subject to certain closing conditions, up to $25.0 million of shares of its Series 8 Non-Convertible Preferred Stock, warrants to purchase up to 22,563,177 shares of common stock and an additional investment right to purchase up to $25.0 million of shares of its Series 9 Convertible Preferred Stock, in a registered offering to a single life sciences institutional investor.
Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Berchman A Vaz, MD 2701 E Elvira Rd, Tucson, AZ 85706-7124 Ph: (520) 874-7400 | Berchman A Vaz, MD 535 N Wilmot Rd, #101, Tucson, AZ 85711-2600 Ph: (520) 874-7400 |
News Archive
HHS' inspector general's office is launching an in-depth investigation into cases where Medicare hospice beneficiaries get inpatient care, following unusual billing patterns that surfaced during recent research on the $1.1 billion industry.
Emerging Healthcare Solutions, Inc. disclosed today that the Company has executed a Term Sheet with Stand-By Systems. The Term Sheet represents successful negotiations between the two companies just ahead of finalizing a Definitive Agreement. Stand-By Systems (SBS) owns the FDA approved SBS 1615 catalytic oxygen generator and associated systems. This cutting edge generator provides medical grade USP oxygen at the push of a button from self-contained inert dry compounds.
A study in the Feb. 1 issue of the journal SLEEP suggests that healthy older adults without sleep disorders can expect to have a reduced "sleep need" and to be less sleepy during the day than healthy young adults.
Cell Therapeutics, Inc. today announced that it has entered into a securities purchase agreement to sell, subject to certain closing conditions, up to $25.0 million of shares of its Series 8 Non-Convertible Preferred Stock, warrants to purchase up to 22,563,177 shares of common stock and an additional investment right to purchase up to $25.0 million of shares of its Series 9 Convertible Preferred Stock, in a registered offering to a single life sciences institutional investor.
Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.
› Verified 5 days ago
Dr. Basel Skeif, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 5140 E Glenn St, Tucson, AZ 85712 Phone: 520-838-3540 Fax: 520-325-3526 | |
Dr. David Spencer Hamilton Sr., MD Rheumatology Medicare: Medicare Enrolled Practice Location: 3601 S 6th Ave, Tucson, AZ 85723 Phone: 520-792-1450 | |
Diana Silva Cantillo, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1230 S Cherrybell Stra, Tucson, AZ 85713 Phone: 520-628-8287 | |
Basel Shoua, M.D Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2070 W Rudasill Rd Ste 130, Tucson, AZ 85704 Phone: 520-797-4468 Fax: 520-797-4502 | |
Hadil Owaynat, DO Rheumatology Medicare: Medicare Enrolled Practice Location: 1501 N Campbell Ave Rm 6336, Tucson, AZ 85724 Phone: 520-626-2760 Fax: 520-626-6020 | |
Dr. David M Schwartz, DO Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 6200 N La Cholla Blvd, Tucson, AZ 85741 Phone: 520-469-8011 Fax: 520-469-8021 | |
Kenneth Alex Murachanian, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 6060 N Fountain Plaza Dr Ste 270, Tucson, AZ 85704 Phone: 520-229-2578 |